Apolipoprotein E, cardiovascular disease and cognitive function in aging women

Neurobiology of Aging

Volumn 26, Issue 4, 2005, Pages 475-484

  Kang, Jae Hee ^a   Logroscino, Giancarlo ^b   De Vivo, Immaculata ^a,b   Hunter, David ^a,b   Grodstein, Francine ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Aging; Apolipoprotein E; Cardiovascular disease; Cognitive performance; Epidemiology

Indexed keywords

APOLIPOPROTEIN E;

AGED; AGING; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; COGNITION; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HEALTH STATUS; HETEROZYGOTE; HUMAN; HYPERTENSION; INTERVIEW; MEDICAL INFORMATION; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; TRANSIENT ISCHEMIC ATTACK; VERBAL MEMORY; WORKING MEMORY;

AGED; AGED, 80 AND OVER; AGING; ALLELES; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; COHORT STUDIES; CONFIDENCE INTERVALS; GENOTYPE; HUMANS; MALE; MEMORY, SHORT-TERM; NEUROPSYCHOLOGICAL TESTS; ODDS RATIO; PUBLIC HEALTH NURSING; RESIDENCE CHARACTERISTICS; RETROSPECTIVE STUDIES; RISK FACTORS; VERBAL LEARNING;

EID: 11844273172     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2004.05.003     Document Type: Article

References (70)

1. Albert M., Smith L.A., Scherr P.A., Taylor J.O., Evans D.A., Funkenstein H.H. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int. J. Neurosci. 57:1991;167-178
2. Alberts M.J., Graffagnino C., McClenny C., DeLong D., Strittmatter W., Saunders A.M., et al. ApoE genotype and survival from intracerebral haemorrhage. Lancet. 346:1995;575
3. Brandt J., Spencer M., Folstein M. The telephone interview for cognitive status. Neuropsychol. Behav. Neurol. 1:1988;111-117
4. Brayne C., Harrington C.R., Wischik C.M., Huppert F.A., Chi L.Y., Xuereb J.H., et al. Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population. Dementia. 7:1996;169-174
5. Bretsky P., Guralnik J.M., Launer L., Albert M., Seeman T.E. The role of APOE-e4 in longitudinal cognitive decline. Neurology. 60:2003;1077-1081
6. Brookmeyer R., Gray S., Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Publ. Health. 88:1998;1337-1342
7. Carmelli D., Swan G.E., Reed T., Miller B., Wolf P.A., Jarvik G.P., et al. Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly persons. JAMA. 50:1998;1580-1585
8. Chen P., Ratcliff G., Belle S.H., Cauley J.A., DeKosky S.T., Ganguli M. Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study. Arch. Gen. Psychiatry. 58:2001;853-858
9. Chey J., Kim J.W., Cho H.Y. Effects of apolipoprotein E phenotypes on the neuropsychological functions of community-dwelling elderly individuals without dementia. Neurosci. Lett. 289:2000;230-234
10. Colditz G.A., Stampfer M.J., Willett W.C., Stason W.B., Rosner B., Hennekens C.H., et al. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am. J. Epidemiol. 126:1987;319-325
11. Craft S., Asthana S., Schellenberg G.D., Baker L., Cherrier M., Boyt A.A., et al. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann. NY Acad. Sci. 903:2000;222-228
12. Davignon J., Gregg R.E., Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988:1988;1-21
13. Elias M.F., Beiser A., Wolf P.A., Au R., White R.F., D'Agostino R.B. The preclinical phase of Alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch. Neurol. 57:2000;808-813
14. Feskens E.J.M., Havekes L.M., Kalmijn S., de Knijff P., Launer L., Kromhout D. Apolipoprotein e4 allele and cognitive decline in elderly men. BMJ. 309:1994;1202-1206
15. Friedman G., Froom P., Sazbon L., Grinblatt I., Shochina M., Tsenter J., et al. Apolipoprotein E-4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology. 52:1999;244-248
16. Guo Z., Fratiglioni L., Viitanen M., Lannfelt L., Basun H., Fastbom J., et al. Apolipoprotein E genotype and in the incidence of Alzheimer's disease among persons aged 75 years and older: variation by use of antihypertensive medication? Am. J. Epidemiol. 153:2001;225-231
17. Haan M.N., Shemanski L., Jagust W.J., Maniolio T.A., Kuller L. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA. 282:1999;40-46
18. Helkala E.L., Koivisto K., Hanninen T., Vanhanen M., Kervinen K., Kuusisto J., et al. Memory functions in human subjects with different apolipoprotein E phenotypes during a 3-year population-based follow-up study. Neurosci. Lett. 204:1996;177-180
19. Helkala E.-L., Koivisto K., Hänninen T., Vanhanen M., Kervinen K., Kuusisto J., et al. The association of apolipoprotein E polymorphism with memory: a population based study. Neurosci. Lett. 191:1995;141-144
20. Henderson A.S., Easteal S., Jorm A.F., Mackinnon A.J., Korten A.E., Christensen H., et al. Apolipoprotein E allele e4, dementia, and cognitive decline in a population sample. Lancet. 346:1995;1387-1390
21. Hofman A., Ott A., Breteler M.M., Bots M.L., Slooter A.J.C., van Harskamp F., et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 349:1997;151-154
22. Holtzman D.M., Bales K.R., Wu S., Bhat P., Parsadanian M., Fagan A.M., et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103:1999;R15-21
23. Horsburgh K., McCulloch J., Nilsen M., Roses A.D., Nicoll J.A. Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebrak ischaemia. Eur. J. Neurosci. 12:2000;4309-4317
24. Hyman B.T., Gomez-Isla T., Briggs M., Chung H., Nichols S., Kohout F., et al. Apolipoprotein E and cognitive change in an elderly population. Ann. Neurol. 40:1996;55-66
25. Jonker C., Schmand B., Lindeboom J., Havekes L.M., Launer L. Association between apolipoprotein E epsilon 4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch. Neurol. 55:1998;1065-1069
26. Jordan B., Relkin N., Ravdin L., Jacobs A., Bennett A., Gandy S. Apolipoprotein E-epsilon4 associated with chronic traumatic brain injury in boxing. J. Am. Med. Soc. 278:1997;2143-2145
27. Kalmijn S., Feskens E.J.M., Launer L., Kromhout D. Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in elderly persons. Stroke. 27:1996;2230-2235
28. Kang J.H., Grodstein F. Regular use of non-steroidal anti-inflammatory drugs and cognitive function in aging women. Neurology. 60:2003;1591-1597
29. Kim K.W., Youn J.C., Jhoo J.H., Lee D.Y., Lee K.U., Lee J.H., et al. Apolipoprotein E epsilon 4 allele is not associated with the cognitive impairment in community-dwelling normal elderly individuals. Int. J. Geriatr. Psychiatry. 17:2002;635-640
30. Kuusi T., Nieminen M.S., Ehnholm C., Yki-Jarvinen H., Valle M., Nikkila E.A., et al. Apolipoprotein E polymorphism and coronary artery disease: increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients. Arteriosclerosis. 9:1989;237-241
31. Kuusisto J., Koivisto K., Kervinen K., Mykkanen L., Helkala E.L., Vanhanen M., et al. Association of apolipoprotein E phenotypes with late onset Alzheimer's disease: population based study. BMJ. 309:1994;636-638
32. Kuusisto J., Koivisto K., Mykkanen L., Helkala E.L., Vanhanen M., Hanninen T., et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ. 315:1997;1045-1049
33. Laird N.M., Ware J.H. Random-effects models for longitudinal data. Biometrics. 38:1982;963-974
34. Lichtman S., Seliger G., Tycki B., Marder K. Apolipoprotein E and functional recovery from brain injury following post-acute rehabilitation. Neurology. 55:2000;1536-1539
35. Manson J.E., Rimm E.B., Stampfer M.J., Colditz G.A., Willett W.C., Krolewski A.S., et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet. 338:1991;774-778
36. Mortensen E.L., Høgh P. A gender difference in the association between APOE genotype and age-related cognitive decline. Neurology. 57:2001;89-95
37. Nilsson L., Nyberg L., Bäckman L. Genentic variation in memory functioning. Neurosci. Biobehav. Rev. 282:2002;841-848
38. O'Hara R., Yesavage J.A., Kraemer H.C., Mauricio M., Friedman L.F., Murphy G.M.J. The APOE epsilon 4 allele is associated with decline on delayed recall performance in community-dwelling older adults. J. Am. Geriatr. Soc. 46:1998;1493-1498
39. Ott A., Slooter A.J., Hofman A., van Harskamp F., Witteman J.C., Van Broeckhoven C., et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet. 351:1998;1840-1843
40. Peila R., Rodriguez B.L., Launer L. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 51:2002;1256-1262
41. Peila R., White L.R., Petrovich H., Masaki K., Ross G.W., Havlik R.J., et al. Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia Aging Study. Stroke. 32:2001;2882-2889
42. Qui C., Winblad B., Fastbom J., Fratiglioni L. Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD. Neurology. 61:2003;655-660
43. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy B., Minoshima S., et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 334:1996;752-758
44. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. 101:2004;284-289
45. Riley K.P., Snowdon D.A., Saunders A.M., Roses A.D., Mortimer J.A., Nanayakkara N. Cognitive function and apolipoprotein E in very old adults: findings from the Nun Study. J. Gerontol. B: Psychol. Sci. Soc. 55:2000;S69-S75
46. Sabo T., Lomnitski L., Nyska A., Beni S., Maronpot R.R., Shohami E., et al. Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: the allele E3 is neuroprotective whereas E4 increases fatalities. Neuroscience. 101:2000;879-884
47. Saunders A.M., Hulette C., Welsh-Bohmer K.A., Schmechel D.E., Crain B., Burke J.R., et al. Specificity, sensitivity and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet. 348:1996;90-93
48. Schmechel D.E., Saunders A.M., Strittmatter W., Crain B., Hulette C.M., Joo S.H., et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. 90:1993;9649-9653
49. Sheng H., Laskowitz D.T., Bennett E., Schmechel D.E., Bart R.D., Saunders A.M., et al. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J. Cereb. Blood Flow Metab. 18:1998;361-366
50. Skoog I., Hesse C., Aevarsson O., Landahl S., Wahlström J., Fredman P., et al. A population study of ApoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J. Neurol. Neurosurg. Psychiatry. 64:1998;37-43
51. Slooter A.J., Cruts M., Ott A., Bots M.L., Witteman J.C., Hofman A., et al. The effect of APOE on dementia is not through atherosclerosis: the Rotterdam Study. Neurology. 53:1999;1593-1595
52. Slooter A.J., van Duijn C.M., Bots M.L., Ott A., Breteler M.M., De Voecht J., et al. Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam Study. J. Neural. Transm. Suppl. 53:1998;17-29
53. Small B.J., Basun H., Backman L. Three-year changes in cognitive performance as a function of apolipoprotein E genotype: evidence from very old adults without dementia. Psychol. Aging. 13:1998;80-87
54. Small B.J., Fratiglioni L., Viitanen M., Winblad B., Backman L. The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population based sample. Arch. Neurol. 57:2000;839-844
55. Small B.J., Graves A.B., McEvoy C.L., Crawford F.C., Mullan M., Mortimer J.A. Is APOE-epsilon4 a risk factor for cognitive impairment in normal aging? Neurology. 54:2000;2082-2088
56. Small G.W., Ercoli L.M., Silverman D.H., Huang S.C., Komo S., Bookheimer S.Y., et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. 97:2000;6037-6042
57. Soininen H., Partanen K., Pitkanen A., Hallikainen M., Hanninen T., Helisalmi S., et al. Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E 4 allele. Neurology. 45:1995;391-392
58. Staehelin H.B., Perrig-Chiello P., Mitrache C., Miserez A.R., Perrig W.J. Apolipoprotein E genotypes and cognitive functions in healthy elderly persons. Acta Neurol. Scand. 100:1999;53-60
59. Stewart R., Russ C., Richards M., Brayne C., Lovestone S., Mann A. Apolipoprotein E genotype, vascular risk and early cognitive impairment in an African Caribbean population. Dement. Geriatr. Cogn. Disord. 12:2001;251-256
60. Tang M.-X., Maestre G., Tsai W.-Y., Liu X.-H., Feng L., Chung W.-Y., et al. Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotype among elderly African Americans, Caucasians, and Hispanics in New York City. Am. J. Human Genet. 58:1996;574-584
61. van Bockxmeer F.M., Mamotte C.D.S. Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet. 340:1992;879-880
62. Welsh K.A., Butters N., Mohs R.C. The consortium to establish a registry for Alzheimer's disease (CERAD). Neurology. 44:1994;609-614
63. White F., Nicoll J., Roses A., Horsburgh K. Impaired neuronal plasticity in transgenic mice expressing human apolipoprotein e4 compared to e3 in a model of entorhinal cortex lesion. Neurobiol. Dis. 8:2001;611-625
64. Wilson R.S., Bienias J.L., Berry-Kravis E., Evans D.A., Bennett D.A. The apolipoprotein E e2 allele and decline in episodic memory. J. Neurol. Neurosurg. Psychiatry. 73:2002;672-677
65. Wilson R.S., Schneider J.A., Barnes L.L., Beckett L.A., Aggarwal N.T., Cochran E.J., et al. The apolipoprotein E e4 allele and decline in different cognitive systems during a 6-year period. Arch. Neurol. 59:2002;1154-1160
66. Winnock M., Letenneur L., Jacqmin-Gadda H., Dallongeville J., Amouyel P., Dartigues J.F. Longitudinal analysis of the effect of apolipoprotein E epsilon4 and education on cognitive performance in elderly subjects: the PAQUID study. J. Neurol. Neurosurg. Psychiatry. 72:2002;794-797
67. Yaffe K., Cauley J., Sands L., Browner W. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch. Neurol. 54:1997;1110-1114
68. Yip A.G., Brayne C., Easton D., Rubinsztein D.C. Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population. J. Med. Genet. 39:2002;639-643
69. Zakzanis KK, Bolous MI. A meta-analysis of ApoE genotype and neuropsychologic and neuroanatomic changes in preclinical Alzheimer's disease. Clin Neuropsychol 2004, in press.
70. Zhu L., Fratiglioni L., Guo Z., Basun H., Corder E.H., Winblad B., et al. Incidence of dementia in relation to stroke and the apolipoprotein E e4 allele in the very old. Findings from a population-based longitudinal study. Stroke. 31:2000;53-60